Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells

Journal of Pineal Research

Volumn 49, Issue 1, 2010, Pages 45-54

  Cabrera, Javier ^a,b   Negrín, Gledy ^a,b   Estévez, Francisco ^a,b   Loro, Juan ^a,b   Reiter, Russel J ^c   Quintana, José ^a,b  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b Madrid Spain   (Spain)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

cell proliferation; melanogenesis; melanoma; melatonin; p38 mitogen activated protein kinase; SK MEL 1

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 PHENYL 2 PROPIONAMIDOTETRALIN; ACETYLCYSTEINE; G PROTEIN COUPLED RECEPTOR; INDOLEAMINE; LUZINDOLE; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE 14; MONOPHENOL MONOOXYGENASE; PERTUSSIS TOXIN; RECEPTOR BLOCKING AGENT; TROLOX C; UNCLASSIFIED DRUG; 4-PHENYL-2-PROPIONAMIDOTETRALINE; DITERPENE; LUZODIOL; MELATONIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; TETRALIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HORMONE RELEASE; HUMAN; HUMAN CELL; MELANOGENESIS; MELANOMA; NUCLEOTIDE SEQUENCE; PINEAL GLAND FUNCTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES; HUMANS; MELANOMA; MELATONIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, MELATONIN; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES;

EID: 77954323682     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00765.x     Document Type: Article

References (59)

1. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991 12 : 151 180.
2. Hardeland R, Fuhrberg B. Ubiquitous melatonin - presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol 1996 2 : 25 45.
3. Kolar J, Machackova I. Melatonin in higher plants: occurrence and possible functions. J Pineal Res 2005 39 : 333 341.
4. Paredes SD, Korkmaz A, Manchester LC et al. Phytomelatonin: a review. J Exp Bot 2009 60 : 57 69.
5. Tan DX, Hardeland R, Manchester LC et al. The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness. Biol Rev Camb Philos Soc 2009 doi:.
6. Reiter RJ. The pineal and its hormones in the control of reproduction. Endocr Rev 1980 1 : 109 131.
7. Arendt J. Melatonin. Clin Endocrinol 1988 29 : 205 229.
8. Reiter RJ, Tan DX. What constitutes a physiological concentration of melatonin? J Pineal Res 2003 34 : 79 80.
9. Fischer TW, Slominski A, Zmijewski MA et al. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp Dermatol 2008 17 : 713 730.
10. Reppert SM. Melatonin receptors: molecular biology of a new family of G-protein-coupled receptors. J Biol Rhythms 1997 12 : 528 531.
11. Vanecek J. Melatonin inhibits increase of intracellular calcium and cyclic AMP in neonatal rat pituitary via independent pathways. Mol Cell Endocrinol 1995 107 : 149 153.
12. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev 1998 78 : 687 721.
13. 2 melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochem Pharmacol 2002 63 : 587 595.
14. Becker-André M, Wiesenberg I, Schaeren-Wiemers N et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994 269 : 28531 28534.
15. Nosjean O, Ferro M, Coge F et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000 275 : 31311 31317.
16. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009 47 : 109 126.
17. Gitto E, Pellegrino S, Gitto P et al. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res 2009 46 : 128 139.
18. Blask DE, Sauer LA, Dauchy RT et al. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999 59 : 4693 4701.
19. Xi SC, Siu SW, Fong SW et al. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 2001 46 : 52 61.
20. Cos S, Gonzalez A, Guezmes A et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 2006 118 : 274 278.
21. Girgert R, Hanf V, Emons G, Gründker C. Membrane bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 2009 47 : 23 31.
22. Dauchy RT, Blask DE, Dauchy EM et al. Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts. J Pineal Res 2009 47 : 32 42.
23. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010 46 : 270 283.
24. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009 27 : 3 9.
25. Korkmaz A, Reiter RJ, Topal T et al. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009 15 : 43 50.
26. Kadekaro AL, Andrade LN, Floeter-Winter LM et al. MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 2004 36 : 204 211.
27. Fischer TW, Zmijewski MA, Zbytek B et al. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol 2006 29 : 665 672.
28. Martín V, Herrera F, García-Santos G et al. Involvement of protein kinase C in melatonin's oncostatic effect in C6 glioma cells. J Pineal Res 2007 43 : 239 244.
29. Joo SS, Yoo YM. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009 47 : 8 14.
30. Martín-Renedo J, Mauriz JL, Jorquera F et al. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008 45 : 532 540.
31. Rubio S, Estévez F, Cabrera J et al. Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells. J Pineal Res 2007 42 : 131 138.
32. Sainz RM, Mayo JC, Tan DX et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005 63 : 29 43.
33. Sainz RM, Mayo JC, Tan DX et al. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem Biophys Res Comm 2003 302 : 625 634.
34. Bellon A, Ortíz-López L, Ramírez-Rodríguez G et al. Melatonin induces neuritogenesis at early stages in N1E-115 cells through actin rearrangements via activation of protein kinase C and Rho-associated kinase. J Pineal Res 2007 42 : 214 221.
35. García-Navarro A, González-Puga C, Escames G et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007 43 : 195 205.
36. Ram PT, Dai J, Yuan L et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002 179 : 141 150.
37. Tam CW, Mo CW, Yao KM, Shiu SY. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res 2007 42 : 191 202.
38. Souza AV, Visconti MA, Castrucci AM. Melatonin biological activity and binding sites in human melanoma cells. J Pineal Res 2003 34 : 242 248.
39. Brydon L, Petit L, Delagrange P et al. Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology 2001 142 : 4264 4271.
40. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009 44 : 175 200.
41. Radogna F et al. Rapid and transient stimulation of intracellular reactive oxygen species by melatonin in normal and tumor leukocytes. Toxicol Appl Pharmacol 2009 239 : 37 45.
42. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007 26 : 3100 3112.
43. Jiang Z, Xu J, Long M et al. 2, 3, 5, 4′-tetrahydroxystilbene-2-O- beta-D-glucoside (THSG) induces melanogenesis in B16 cells by MAP kinase activation and tyrosinase upregulation. Life Sci 2009 85 : 345 350.
44. Smalley K, Eisen T. The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Lett 2000 476 : 198 202.
45. Pandi-Perumal SR, Trakht I, Srinivasan V et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008 85 : 335 353.
46. Cucina A, Proietti S, D'Anselmi F et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009 46 : 172 180.
47. Roth JA, Kim BG, Lin WL et al. Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 1999 274 : 22041 22047.
48. Quirós I, Sáinz RM, Hevia D et al. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells. Int J Cancer 2009 125 : 1497 1504.
49. Torres F, Quintana J, Díaz JG et al. Trifolin acetate-induced cell death in human leukemia cells is dependent on caspase-6 and activates the MAPK pathway. Apoptosis 2008 13 : 716 728.
50. Cos S, Recio J, Sánchez-Barceló EJ. Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci 1996 58 : 811 816.
51. Densham RM, Todd DE, Balmanno K et al. ERK1/2 and p38 cooperate to delay progression through G1 by promoting cyclin D1 protein turnover. Cell Signal 2008 20 : 1986 1994.
52. Slominski A, Pruski D. Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res 1993 206 : 189 194.
53. Slominski A, Tobin DJ, Shibahara S et al. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004 84 : 1155 1228.
54. Finn GJ, Creaven BS, Egan DA. Activation of mitogen activated protein kinase pathways and melanogenesis by novel nitro-derivatives of 7-hydroxycomarin in human malignant melanoma cells. Eur J Pharm Sci 2005 26 : 16 25.
55. Saha B, Singh SK, Sarkar C et al. Activation of the Mitf promoter by lipid-stimulated activation of p38-stress signalling to CREB. Pigment Cell Res 2006 19 : 595 605.
56. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38 (MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009 15 : 369 379.
57. Thangasamy T, Sittadjody S, Limesand KH et al. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol 2008 30 : 371 387.
58. Jahnke G, Marr M, Myers C et al. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999 50 : 271 279.
59. Seabra ML, Bignotto M, Pinto LR Jr. et al. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000 29 : 193 200.